Yasutomo Nasu

Yasutomo Nasu

Auto-generated profile, based on publicly available information

Yasutomo Nasu

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in BJU International
Verified
Journal Article
Closed access
PDF file
YYY. Yamamoto
Y. Yamamoto
YNY. Nasu
Y. Nasu
TST. Saika
T. Saika
TAT. Akaeda
T. Akaeda
TTT. Tsushima
T. Tsushima
HKH. Kumon
H. Kumon

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
NXNaijin Xu
Naijin Xu
WLWenfeng Lin
Wenfeng Lin
JSJingkai Sun
Jingkai Sun
TSTakuya Sadahira
Takuya Sadahira
AXAbai Xu
Abai Xu
PHPeng HUANG
Peng HUANG
Nitroxoline is considered to be an effective treatment for the urinary tract infections. Recently, it has been found to be effective against several cancers. However, few studies have examined the anti-tumor activity of nitroxoline in bladder cancer. The purpose of the study was to reveal the possible mechanisms how nitroxoline inhibited bladder cancer progression. In vitro assay, we demonstrated that nitroxoline inhibited bladder cancer cell growth and migration in a concentration-related manner. Western blot analysis demonstrated that nitroxoline downregulated the expressions of epithelial mesenchymal transition (EMT)-related proteins. Furthermore, treatment with nitroxoline in the C3H/He mice bladder cancer subcutaneous model resulted in significant inhibition of tumor growth. Moreover, the percentage of myeloid‐derived suppressor cells (MDSC) in peripheral blood cells significantly decreased after treatment of nitroxoline. Taken together, our results suggested that nitroxoline may be used as a potential drug for bladder cancer.

1 January 2021 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
YMYosuke Mitsui
Yosuke Mitsui
TSTakuya Sadahira
Takuya Sadahira
YMYuki Maruyama
Yuki Maruyama
RSRyota Sato
Ryota Sato
ARAcosta Gonzalez Herik Rodrigo
Acosta Gonzalez Herik Rodrigo
YNYasutomo Nasu
Yasutomo Nasu
Mitsui Y, et al. World J Mens Health. 2020 Jan;38:e60. https://doi.org/10.5534/wjmh.200036

1 January 2021 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
KYKasumi Yoshinaga
Kasumi Yoshinaga
TSTakuya Sadahira
Takuya Sadahira
YMYuki Maruyama
Yuki Maruyama
YMYosuke Mitsui
Yosuke Mitsui
TITakehiro Iwata
Takehiro Iwata
YNYasutomo Nasu
Yasutomo Nasu
Yoshinaga K, et al. Investig Clin Urol. 2020 Aug;62:e1. https://doi.org/10.4111/icu.20200103

1 January 2021 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
ITIchiro Tsuboi
Ichiro Tsuboi
YMYuki Maruyama
Yuki Maruyama
TSTakuya Sadahira
Takuya Sadahira
NANobuyoshi Ando
Nobuyoshi Ando
YNYasuhiro Nishiyama
Yasuhiro Nishiyama
YNYasutomo Nasu
Yasutomo Nasu
Tsuboi I, et al. Investig Clin Urol. 2021 May;62(3):298-304. https://doi.org/10.4111/icu.20200450

20 February 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MNMasanori Noguchi
Masanori Noguchi
GAGaku Arai
Gaku Arai
SEShin Egawa
Shin Egawa
COChikara Ohyama
Chikara Ohyama
SNSeiji Naito
Seiji Naito
KIKyogo Itoh
Kyogo Itoh
214 Background: A novel cancer vaccine consisting of 20 mixed peptides (KRM-20) was designed to induce cytotoxic T lymphocytes (CTL) against twelve different tumor-associated antigens. The aim of this phase 2 trial was to examine whether KRM-20 in combination with docetaxel and dexamethasone enhances anti-tumor effects in patients with castration-resistant prostate cancer (CRPC). Methods: In this double-blind, placebo-controlled, randomized, phase 2 study, we enrolled chemotherapy-naïve patients with progressive CRPC from 10 medical centers in Japan. Eligible patients were randomly assigned 1:1 centrally to either KRM-20 combined with docetaxel and dexamethasone or placebo with docetaxel and dexamethasone. Patients initially received 5 weekly subcutaneous KRM-20 (20 mg) or placebo injections with daily oral dexamethasone (1 mg) following 5 courses of docetaxel (70 mg/m2 every 3 weeks). The primary endpoint was to compare each treatment for prostate-specific antigen (PSA) decline. Results: Between Jul 31, 2013 and Jul 11, 2014, 51 patients were enrolled to the trial: 25 were assigned to the KRM-20 arm, and 26 were allocated to the placebo arm. Mean % PSA levels from baseline in the KRM-20 arm significantly decreased during the treatment compared witht those in the placebo arm (P = 0.028, MANOVA). Human leukocyte antigen matched peptide-specific immunoglobulin G (P = 0.018) and CTL (P = 0.007) responses in the KRM-20 arm significantly increased after the treatment. The appearance of myeloid-derived suppressor cells in the KRM-20 arm significantly decreased after the treatment (P = 0.007). The addition of KRM-20 did not result in increased toxicity. There was no between-group differences in progression-free or overall survival. Conclusions: These findings suggest potential clinical benefits for the combined use of KRM-20 with docetaxel and dexamethasone in patients with CRPC. Clinical trial information: UMIN000011028.